Showing results (111-120 of 134) with videos related to
Sort By:
Pageof 14
Pharmaceutics|September 28, 2021
PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5'-Diphospho-glucuronosyltransferase SubstratesMicaela B Reddy, Michael B Bolger, Grace Fraczkiewicz, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 9, 2025
Prediction of hepatic metabolic clearance in rats and dogs using long-term cocultured hepatocytesKenichi Umehara, Florian Klammers, Isabelle Walter, et al.European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 17, 2019
Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption: An UNGAP reviewMaria Vertzoni, Patrick Augustijns, Michael Grimm, et al.Pharmaceutical Research|July 19, 2014
Quantitative ADME proteomics - CYP and UGT enzymes in the Beagle dog liver and intestineAki T Heikkinen, Arno Friedlein, Mariette Matondo, et al.Journal of Medicinal Chemistry|July 5, 2022
Design and Measurement of Drug Tissue Concentration Asymmetry and Tissue Exposure-Effect (Tissue PK-PD) EvaluationRichard Zang, Aline Barth, Harvey Wong, et al.Pharmaceutics|September 28, 2021
Safety Testing of an Antisense Oligonucleotide Intended for Pediatric Indications in the Juvenile Göttingen Minipig, including an Evaluation of the Ontogeny of Key NucleasesAllan Valenzuela, Claire Tardiveau, Miriam Ayuso, et al.Drug Metabolism and Pharmacokinetics|January 6, 2026
Future directions in drug-drug interaction evaluations: Industry perspective on the ICH M12 guidanceKenichi Umehara, Andrew Harrell, Chandra Prakash, et al.CPT: Pharmacometrics & Systems Pharmacology|June 20, 2019
Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic ModelYuan Chen, Tamara D Cabalu, Ernesto Callegari, et al.Journal of Medicinal Chemistry|January 18, 2020
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum DisorderPatrick Schnider, Caterina Bissantz, Andreas Bruns, et al.The Journal of Pharmacology and Experimental Therapeutics|August 19, 2011
CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitorLothar Lindemann, Georg Jaeschke, Aubin Michalon, et al.Pageof 14